isabelobrien, Author at European Medical Journal - Page 18 of 29

Does pharma have the power to turn back time?

Finding a way to combat the negative effects of ageing could save healthcare systems millions. Learn whether ageing could be the next big pharma market to take the world by storm.

Orphan drugs face new pressures

The orphan drug market has seen robust growth over the past decade, but may face challenges in maintaining its trajectory due to evolving investor and payer preferences.

Roundtable: How can pharma close the gender health gap?

Robyn Widenmaier (GSK) and Tabetha Sundin (AstraZeneca) discuss whether bids to improve gender parity could be the ticket to change in women’s health.

Spotlight: March 2024

Catch up on March’s top pharma news, including companies slashing inhaler costs and new hope for the UK life sciences sector.

Say hello to EMJ GOLD!

Join us for the next chapter of GOLD as we launch on our new home here on the EMJ website, providing you with a one-stop-shop for all your healthcare content needs.

Spotlight: February 2024

GOLD looks back on some of the top pharma news stories from the past month, including new approvals, the latest appointments and departures in the industry and more.

Has medical affairs reached 'strategic pillar' standing?

The value of medical affairs is not up for debate, but are companies allocating enough time and resources to make it the strategic function it can be?

Haematology under the microscope

This infographic explores the vastness of the haematology market, including key industry players, drugs to watch, the global burden of haematological diseases and more.

Cardiology under the microscope

This infographic explores the ins and outs of the cardiology market, including market size, top pharmaceutical and medical device players and the regional impact of cardiovascular disease.

Oncology under the microscope

This infographic explores the intricacies of the oncology market, assessing its impact on patients, its global market share and the new drugs to watch in the oncology space.